Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells

Leukemia Research

Volumn 27, Issue 5, 2003, Pages 437-444

  Shaker, Sepideh ^a   Bernstein, Mark ^b   Momparler, Louise F ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

5 Aza 2 deoxycytidine; Antineoplastic activity; Depsipeptide; DNA methylation; Histone deacetylase; Trichostatin A

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DEPSIPEPTIDE; FR 901228; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CLONOGENESIS; DEACETYLATION; DNA SYNTHESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; METHYLATION; MYELOID LEUKEMIA; PRIORITY JOURNAL;

ACETYLATION; ACUTE DISEASE; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; AZACITIDINE; CELL DIVISION; DEPSIPEPTIDES; DNA METHYLATION; DNA REPLICATION; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; HL-60 CELLS; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID; NEOPLASM PROTEINS; PEPTIDES, CYCLIC; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0037400558     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00222-9     Document Type: Article

References (41)

1. Lotem J., Sachs L. Different blocks in differentiation of myeloid leukemia cells. Proc. Natl. Acad. Sci. U.S.A. 71:1974;3507-3511.
2. Koeffler H.P. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 62:1983;709-721.
3. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 21:1999;163-167.
4. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis. Trends Genet. 16:2000;168-174.
5. Momparler R.L., Bovenzi V. DNA methylation and cancer. J. Cell Physiol. 183:2000;145-154.
6. Cameron E.E., Kurtis E., Myöhänen B.S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:1999;103-107.
7. Kawano S., Miller C.W., Gombart A.F., Bartram C.R., Matsuo Y., Asou H.et al. Loss of p73 gene expression in leukemia/lymphomas due to hypermethylation. Blood. 94:1999;1113-1120.
8. Liu M., Taketani T., Li R., Takita J., Taki T., Yang H.et al. Loss of p73 gene expression in lymphoid leukemia cell lines is associated with hypermethylation. Leuk. Res. 25:2001;441-447.
9. Pinto A., Attadia V., Fusco L.A., Ferrara F., Spada O.A., DiFiore P. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia. Blood. 64:1984;922-929.
10. Momparler R.L., Doré B.T., Momparler L.F. Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells. Cancer Lett. 54:1990;21-28.
11. Rivard G.E., Momparler R.L., Demers J., Benoit P., Raymond R., Lin K.T.et al. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia. Leuk. Res. 5:1981;453-462.
12. Momparler R.L., Rivard G.E., Gyger M. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharma. Ther. 30:1985;277-286.
13. Richel D.J., Colly L.P., Kluin-Nelemans J.C., Willemze R. The antileukaemic activity of 5-aza-2′-deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. Br. J. Cancer. 64:1991;144-148.
14. Marks P.A., Richom V.M., Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:2000;1210-1216.
15. Wolffe A.P. Histone deacetylase: a regulator of transcription. Science. 272:1996;371-372.
16. Archer S.Y., Hoddin R.A. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 9:1999;171-174.
17. Yoshida M., Kijima M., Akita M., Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265:1990;17174-17179.
18. Kosugi H., Towatari M., Hatano S., Kitamura K., Kiyoi H., Kinoshita T.et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia. 13:1999;1316-1324.
19. Wang J., Saunthararajah Y., Redner R.L., Liu J.M. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemic cells. Cancer Res. 59:1999;2766-2769.
20. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I.et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7:2001;971-976.
21. Jones P.L., Veenstra G.J., Wade P.A., Vermaak D., Kass S.U., Landsberger N.et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19:1998;187-191.
22. Bovenzi V., Momparler R.L. Antineoplastic action and expression of retinoic acid receptor β gene in breast carcinoma cells treated with 5-aza-2′-deoxycytidine and a histone deacetylase inhibitor. Cancer Chem. Pharmacol. 48:2001;71-76.
23. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinoushi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 41:1998;126-133.
24. Byrd J.C., Shinn C., Ravi R., Willis C.R., Waselenko J.K., Flinn L.W.et al. Depsipeptide (FR981228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 94:1999;1401-1408.
25. Ueda H., Manda T., Matsumoto S., Mukumoto S., Nishigaki F., Kawamura I.et al. FR901228, a novel antitumor antibiotic bicyclic depsipeptide produced by Chromobacterium violaceum no. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiotics. 47:1994;315-323.
26. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N.et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 393:1998;386-389.
27. Lin K.T., Momparler R.L., Rivard G.E. High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J. Pharma. Sci. 70:1981;1228-1232.
28. Momparler R.L. In vitro systems for evaluation of combination chemotherapy. Pharma. Ther. 8:1980;21-25.
29. Löwenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. New Engl. J. Med. 341:1999;1051-1062.
30. Flasshove M., Meusers P., Schutte J., Noppeney R., Beelen D.W., Sohrab S.et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukemia. Ann. Hematol. 79:2000;533-542.
31. Warrell R.P. Jr., He L.Z., Richon V., Calleja E., Pandolfi P.P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90:1998;1621-1625.
32. Sacchi S., Kantarjian H.M., O'Brien S., Cortes J., Rios M.B., Giles F.J.et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 86:1999;2632-2641.
33. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M.et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18:2000;956-962.
34. Momparler R.L., Momparler L.F., Samson J. Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-β-D-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk. Res. 8:1984;1043-1049.
35. Wilson V.L., Jones P.A., Momparler R.L. Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as possible mechanism of chemotherapeutic action. Cancer Res. 43:1983;3493-3496.
36. Momparler R.L., Bouchard J., Onetto N., Rivard G.E. 5-AZA-2′-deoxycytidine in patients with acute leukemia inhibits DNA methylation. Leuk. Res. 8:1984;181-185.
37. Rajgolikar G., Chan K.K., Wang H.R. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 51:1998;29-38.
38. Weiser T.S., Guo Z.S., Ohnmacht G.A., Parkhurst M.L., Tong-On P., Marincola F.M.et al. Sequential 5-Aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J. Immunother. 24:2001;151-161.
39. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J.et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 8:1997;358-368.
40. Gore SD, Carducci MA. Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Exp. Opin. Invest. Drugs 2000;9:2923-34.
41. Momparler R.L. Molecular cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharma. Ther. 30:1985;287-299.